Articles tagged with Human Immunodeficiency Virus
Researchers found that fingolimod inhibits multiple stages of the HIV lifecycle, blocking infection and transmission in CD4+ T cells. The study suggests that targeting Sphingosine-1-phosphate receptors could be a novel strategy to inhibit HIV replication.
Researchers found that fingolimod inhibits HIV replication by targeting S1P receptors, reducing viral binding and fusion. The compound also activates antiviral restriction factor SAMHD1, leading to a decrease in total and integrated HIV levels.
A new study found that short-term use of pre-exposure prophylaxis (PrEP) medication can effectively prevent HIV transmission in men who have sex with men. During a vacation, 94% of participants had blood concentrations protective against HIV, while no transmissions occurred during the trip itself.
A single protein, MARCH8, uses multiple strategies to defend cells against viral infection, including tagging the vesicular stomatitis virus for destruction and holding HIV hostage. This discovery could improve understanding of how HIV overcomes human immune defense.
Physicist John Barton at UC Riverside has received a $1.86 million NIH grant to develop methods for understanding how pathogens like HIV evolve and escape the immune system. His research could lead to the design of new and better treatments to fight disease.
Researchers at The Wistar Institute identified a cell-surface glycomic signature associated with persistent HIV transcription in T cells. This signature, characterized by the presence of fucose and Sialyl-LewisX, may help target hidden HIV reservoirs during antiretroviral therapy.
A new study finds that providers participating in an intervention with education and resources are more likely to adhere to national chronic opioid therapy guidelines compared to those who do not take part. The intervention includes access to a nurse care manager, addiction specialists, and monitoring of prescription usage.
A new study found that HIV screening every three months compared to annually improves clinical outcomes and is cost-effective among high-risk YMSM in the US. The study also suggests that more frequent screening could lead to improved life expectancy and reduced HIV transmission among these men.
A study by Radboud University Medical Center found that a single pill of dolutegravir per day is equally effective as a combination therapy in children, reducing dosage complexity and increasing treatment accessibility. This simplified dosing regimen has been integrated into World Health Organization guidelines and FDA approval.
The special collection highlights RWHAP's strategies for improving HIV care, including pre-exposure prophylaxis (PrEP), data analysis, and collaborative efforts. HRSA's program serves over half a million people in the US annually, achieving high viral suppression rates.
A six-week course of a PCSK9 inhibitor improved coronary artery function in people living with HIV or high cholesterol, increasing area and blood flow. The study suggests a potential way to limit cardiovascular disease risk in these populations by improving blood vessel function.
A new NIH study demonstrates that kidney transplantation between people with HIV can be done safely and effectively. The study found excellent graft survival rates, comparable to those of recipients receiving kidneys from HIV-negative donors, without significant differences in infection or adverse events rates.
A new study found the prevalence of chronic kidney disease (CKD) among Mexican Americans has doubled in recent years, while stabilizing for other racial/ethnic and socioeconomic groups. Researchers also developed a gene therapy that can alleviate obstructive sleep apnea by stimulating the nerve that contracts muscles in the tongue.
A new assay detects intact HIV latent proviruses at higher frequencies than previous methods, revealing a significant amount of intact virus in infected individuals; this finding is crucial for developing an HIV cure. The study provides a benchmark for assessing persistent proviral DNA and its composition.
A GW-led research team is investigating HIV-1 resistance to antibody treatments, aiming to develop effective combination therapies for treatment, prevention, and potential cure. The project, funded through April 2025, aims to identify effective combination antibody cocktails that limit the virus's ability to escape from antibody pressure.
Physicists at University of Utah pioneered a method to image virus-like particles in real time, revealing the lattice's dynamic nature. The discovery opens up potential new therapies by understanding how Gag and GagPol proteins rearrange, leading to viral maturation.
A study by Rutgers researchers found that 19% of participants had their first sexual experience before age 13, with same-sex encounters happening on average at 14.5 years.
A national quality improvement collaborative found that making primary care practices more inclusive improves STD and HIV screening rates among LGBT individuals. The program increased estimated HIV screening from 14.8% to 30.5% at participating sites.
A large study found increased risk of heart disease, chronic liver and kidney disease, and physical function impairment in people with HIV. The study aims to develop effective prevention strategies and guidelines for cardiovascular risk management in this population.
A new study identifies key steps toward establishing nurse- and midwife-led HIV services in eastern and southern Africa, including improved training, supportive supervision, and formal mentorship programs. The region has shown remarkable progress toward eliminating HIV, but challenges remain in providing effective antiretroviral therapy.
A new long-acting injectable form of PrEP containing cabotegravir outperformed a daily oral Truvada regimen in preventing HIV acquisition among men who have sex with men and transgender women. The study found that the injectable PrEP had a superior protective effect, with a 66% lower incidence rate compared to the daily pill.
The HPTN 083 clinical trial showed that a long-acting cabotegravir injection was superior to daily oral tenofovir/emtricitabine for HIV prevention among cisgender men and transgender women. The study found a 66% reduction in incident HIV infections in participants given cabotegravir compared to TDF/FTC.
A Rutgers-led study finds that incarceration and police discrimination contribute to higher rates of psychological distress, HIV risk, and lower willingness to take PrEP among Black gay, bisexual, and other sexual minority men. The research highlights the need for anti-racist and anti-heterosexist advocacy and interventions to address ...
Researchers found that HIV-positive adults' brains process speech cues differently, with disrupted responses even when hearing tests are normal. This non-invasive test holds promise for understanding brain dysfunction in HIV and other disorders.
Researchers report a lower incidence of COVID-19 among HIV-positive patients receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) therapy. Further investigation is warranted to understand the findings' implications for HIV preexposure prophylaxis and randomized trials.
Scientists at Sanford Burnham Prebys have developed a new drug called Ciapavir that effectively reactivates dormant human immunodeficiency virus (HIV) without overactivating the immune system. This approach, called 'shock and kill,' aims to create a functional HIV cure by eliminating all pockets of dormant HIV.
Yale researchers identified four approved drugs that can suppress HIV reactivation and reduce damaging immune responses. These drugs, including ruxolitinib and mycophenolic acid, show promise as a complement to antiretroviral therapy in treating HIV infection.
The Pew Charitable Trusts has selected 10 postdoctoral fellows from seven Latin American countries to conduct research in the US. The fellows will explore various biomedical topics, including leukemia stem cells and HIV hiding inside host cells.
Researchers found that astrocytes in the brain can harbor HIV and spread it to immune cells that travel to other organs, even when treated with combination antiretroviral therapy. The study suggests that HIV reservoirs in the brain must be targeted for effective cure strategies.
New studies from Flinders University highlight key areas for improvement in HIV management in developing countries, particularly in sub-Saharan regions. Nutritional programs should address underlying challenges like poverty and food insecurity, while prisons often struggle with optimal HIV care due to stigma and resource limitations.
Researchers at Yale University have discovered a molecular explanation for how HIV hides in immune system cells, allowing it to remain dormant and re-emerge. By understanding this process, scientists may develop new ways to control HIV infection.
A new type of vaccination has been shown to substantially enhance and sustain protection from HIV in monkeys, with a two-armed approach stimulating both serum and cellular immunity. The findings have broad implications for immunologists pursuing vaccines for other diseases, particularly those caused by coronaviruses.
Researchers found that L-thyroxine therapy did not improve symptoms, quality of life, or handgrip strength in older adults with subclinical hypothyroidism and high symptom burden. This study's results do not support routine use of L-thyroxine for this population.
Researchers have identified a new potential reservoir of latent HIV, specifically CD127 cells in tissues, which harbor the virus's genetic material but silence its expression. These cells may be targeted for an HIV cure, offering hope for developing an effective treatment.
New research on the structure of HIV has revealed a promising novel drug target that can prevent further infection by targeting the genetic code. This discovery offers hope for more effective treatments and potentially fewer side effects for HIV patients.
A qualitative study found that women living with HIV prefer long-acting injectable (LAI) antiretroviral therapy due to its convenience, privacy, and perceived effectiveness. However, they also raised concerns about access, mistrust, and medical burden.
Research highlights increased cardiovascular disease risk among people with HIV worldwide, particularly in sub-Saharan Africa. The study explores how geographic location and income level influence the distribution of cardiovascular risk factors, shedding light on potential differences between lower- and higher-income countries.
Researchers identified a key HIV mechanism for viral adaptation to immune milieus. Lower Rev-RRE activity has been linked to slower disease progression and immune evasion, highlighting the potential for therapeutic targets.
Researchers have successfully developed a new, efficient method to create water-soluble fullerene compounds with high anti-HIV activity. This breakthrough could pave the way for new-generation drugs based on these compounds, offering hope for treating human immunodeficiency virus (HIV).
A multinational study of over 640 pregnant women with HIV found that regimens containing dolutegravir were more effective in suppressing HIV than a commonly used regimen containing efavirenz. Nearly 98% of women who received either of the DTG-containing regimens were virally suppressed at delivery, while only 91% of those receiving EFV...
A study of a second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy. The patient had a healthy CD4 cell count, suggesting they have recovered well from the transplant.
Researchers found that a community-based intervention using mobile vans significantly increased viral suppression, with 74% of participants achieving suppression compared to 63% in traditional clinics. The convenience of the vans made it easier for people living with HIV to access treatment.
A new approach using harmless viruses to deliver antibody genes has led to sustained production of HIV antibodies for over a year in a NIH clinical trial. The technology shows promise for preventing and treating various infectious diseases with further development.
Researchers found that starting ART immediately after HIV infection significantly reduces viral reservoirs, making them 100 times smaller. This discovery provides new hope for eradicating the virus.
People living with HIV in Ontario have a 34% higher incidence rate of COPD, diagnosed at 50 years old vs. 62 for HIV-negative individuals, according to a study led by St. Michael's Hospital researchers. The study also found that women with HIV have a 54% higher risk of COPD.
A recent study published in the journal AIDS found that vitamin E improves liver function and reduces fat in patients with nonalcoholic steatohepatitis (NASH) and HIV. The treatment was well-tolerated and showed more significant improvements than reported in the general population.
A new study finds that fewer than one in four gay, bisexual and questioning teenage boys have ever received an HIV test, despite high risk of transmission. The study identified factors that increase the likelihood of testing, including frank conversations with doctors about sexual health and testing.
A digital intervention program called Run4Love, tested on the popular Chinese social media app WeChat, significantly reduced depressive symptoms and stress among people living with HIV. The study found a promising approach to addressing mental health gaps in resource-limited settings.
A study from George Washington University found that apolipoprotein A-I binding protein (AIBP) inhibits HIV-1 replication by targeting lipid rafts and reducing virus-cell fusion. This innate immunity factor provides a novel target for developing new therapeutic approaches to inhibit HIV infection.
A study of over 1,000 youth found that only 12% achieved viral suppression, compared to 32-63% in adult studies. The study highlights the need for tailored HIV intervention services and frequent contact with trained peer counselors to ensure enrollment and retention in care.
A new study called DELIVER will enroll 750 healthy, HIV-negative pregnant women to test the safety of two HIV prevention methods: a monthly dapivirine vaginal ring and daily Truvada. The study aims to provide much-needed information about these products' safety in pregnant women, an area currently lacking in data.
Researchers calculated average initial HIV ART regimen costs from 2012 to 2018, finding a significant decrease in some regions and a steady increase in others. The study highlights the impact of high ART costs on HIV treatment outcomes in the US.
A Phase 2b/3 study in South Africa found that an investigational prime-boost vaccine regimen did not prevent HIV, but participants were safe. Researchers are continuing to explore other approaches to a safe and effective HIV vaccine.
Researchers have found that combining two anti-HIV antibodies with ART can suppress the virus and boost T cell responses, offering new hope for HIV treatment. The study suggests a potential interaction between humoral immunity and cell-mediated immunity, which could lead to improved control of the virus.
A novel HIV antibody, 1-18, has been identified as a highly potent and effective treatment option. Unlike other antibodies, it prevents the development of viral resistance, maintaining suppressed viral loads for extended periods.
Patients living with HIV who attend religious services regularly experience higher emotional and physical well-being, while privately religious individuals face mental health challenges. Researchers suggest integrating spiritual beliefs into holistic treatment programs to improve health outcomes.
Researchers discovered the structure of HIV intasomes while they were blocked by key drugs, revealing how these medications inhibit viral infection. The study provides valuable information to design and improve future treatments.
A new study suggests that state-purchased insurance plans are improving HIV outcomes for people living with the disease. The research found that increased enrollment in these programs is associated with better viral suppression rates, which can lead to a reduction in new HIV transmissions and healthcare costs.
Scientists reactivated resting immune cells infected with HIV or SIV, allowing viruses to be neutralized by anti-HIV drugs and the immune system. The study uses a compound called AZD5582, which activates latent cells without causing toxicity.
Scientists at UNC-Chapel Hill and Emory University successfully reversed HIV latency in animal models using compound AZD5582. The study, published in Nature, demonstrated the ability to activate latently infected CD4+ T cells without toxicity, paving the way for further research towards a cure.